Heightening Focus On Hemp, Cannabis, US FDA Hires Norman Birenbaum As Public Health Advisor
Executive Summary
Hemp industry and private attorneys glad Birenbaum, who was the chief cannabis policy advisor to governors of New York and Rhode Island, given prominent role at FDA that could spur regulatory action.
You may also be interested in...
US FDA Doubts Hemp ‘Derivatives Created From Scratch’ Belong In Lawful Use Pathway
States’ histories with legalizing cannabis aren’t good models for an hemp regulatory pathway, says FDA hemp and cannabis policy chief Norman Birenbaum. Influence from those models already seen in US with ingredients including delta-8 THC marketed as hemp as defined in federal law de-scheduling it as a controlled substance.
Is US Hemp Policy Heading For Farm Bill, Act III?
It could take next farm bill, on lawmakers’ 2023 to-do list, to extinguish inferno of disagreement between FDA and regulated industries over lawful use of hemp-based ingredients in supplements as well as food and non-drug topicals. Before 2018 bill de-scheduled hemp, 2014 bill expanded access to hemp for research.
Worldwide Regulators Warm Up To Medical Marijuana
Both the US and EU are gradually warming up to medical marijuana, but clunky and inadequate regulation threatens to curtail the growth of a burgeoning industry.